In the current study, we evaluated the efficiency of
folate-
polyamidoamine dendrimers conjugates (FA-PAMAM) for the in situ delivery of therapeutic
antisense oligonucleotides (ASODN) that could inhibit the growth of C6
glioma cells.
Folic acid was coupled to the surface amino groups of G5-PAMAM
dendrimer (G5D) through a 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide bond, and ASODNs corresponding to rat
epidermal growth factor receptor (EGFR) were then complexed with FA-PAMAM. At an ASODN to PAMAM ratio of 16:1,
agarose electrophoresis indicated that
antisense oligonucleotides were completely complexed with PAMAM or FA-PAMAM. The ASODN transfection rates mediated by FA-PAMAM and PAMAM were superior to
oligofectamine, resulting in greater suppression of EGFR expression and
glioma cell growth. Stereotactic injection of EGFR ASODN:FA-PAMAM complexes into established rat C6 intracranial
gliomas resulted in greater suppression of
tumor growth and longer survival time of
tumor-bearing rats compared with PAMAM and
oligofectamine-mediated EGFR-ASODN
therapy. The current study demonstrates the suitability of
folate-
PAMAM dendrimer conjugates for efficient EGFR ASODN delivery into
glioma cells, wherein they release the ASODN from the FA-PAMAM to knock down EGFR expression in C6
glioma cells, both in vitro and in vivo. FA-PAMAM may thus represent a novel delivery system for short
oligonucleotides in
glioma-targeted
therapy.